Cyclin Dependent Kinase Inhibitor Market

Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent kinase controls cell cycle progression, transcription, mRNA processing, and differentiation. Cyclin-dependent kinase inhibitor arrest cell cycle at the G1 phase leading to mitosis. Cyclin-dependent kinase inhibitors are employed in the treatment of cancers by preventing over proliferation of cancer cells. Cyclin-dependent kinase are very active in most cancers which is rational to the use of cyclin-dependent kinase inhibitor as anti-cancer agents.
Cyclin Dependent Kinase Inhibitor Market contains market size and forecasts of Cyclin Dependent Kinase Inhibitor in Global, including the following market information:
Global Cyclin Dependent Kinase Inhibitor Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cyclin Dependent Kinase Inhibitor market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Broad CDK inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cyclin Dependent Kinase Inhibitor include Eli Lilly, Pfizer, Novartis, Astex Pharmaceuticals, Merck, Bio-Techne, Sanofi, Bayer and Syros Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cyclin Dependent Kinase Inhibitor companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cyclin Dependent Kinase Inhibitor Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cyclin Dependent Kinase Inhibitor Market Segment Percentages, by Type, 2021 (%)
Broad CDK inhibitors
Specific CDK inhibitors
Global Cyclin Dependent Kinase Inhibitor Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cyclin Dependent Kinase Inhibitor Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Cyclin Dependent Kinase Inhibitor Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cyclin Dependent Kinase Inhibitor Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cyclin Dependent Kinase Inhibitor revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cyclin Dependent Kinase Inhibitor revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Pfizer
Novartis
Astex Pharmaceuticals
Merck
Bio-Techne
Sanofi
Bayer
Syros Pharmaceuticals
Amgen
BioCAD
Otsuka Pharmaceutical